132 related articles for article (PubMed ID: 23666576)
1. Contributing factors to the apparent clearance of bepridil in patients with paroxysmal or persistent atrial fibrillation: analysis using population pharmacokinetics.
Shiga T; Hashiguchi M; Naganuma M; Suzuki A; Hagiwara N
Ther Drug Monit; 2013 Jun; 35(3):367-73. PubMed ID: 23666576
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome in patients with paroxysmal or persistent atrial fibrillation receiving bepridil.
Shiga T; Suzuki A; Naganuma M; Hosaka F; Shoda M; Hagiwara N
Circ J; 2011; 75(6):1334-42. PubMed ID: 21483159
[TBL] [Abstract][Full Text] [Related]
3. Beta-blocker decreases the increase in QT dispersion and transmural dispersion of repolarization induced by bepridil.
Yoshiga Y; Shimizu A; Yamagata T; Hayano T; Ueyama T; Ohmura M; Itagaki K; Kimura M; Matsuzaki M
Circ J; 2002 Nov; 66(11):1024-8. PubMed ID: 12419934
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter.
Yasuda M; Nakazato Y; Sasaki A; Kawano Y; Nakazato K; Tokano T; Daida H
Circ J; 2006 Jun; 70(6):662-6. PubMed ID: 16723784
[TBL] [Abstract][Full Text] [Related]
5. Carvedilol is effective and safe in combination with bepridil for persistent atrial fibrillation and decreases the QT prolongation induced by bepridil therapy.
Kawamura M; Munetsugu Y; Tanno K; Kobayashi Y
J Cardiovasc Pharmacol; 2013 Jan; 61(1):77-82. PubMed ID: 23107870
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs.
Miyaji K; Tada H; Fukushima Kusano K; Hashimoto T; Kaseno K; Hiramatsu S; Tadokoro K; Naito S; Nakamura K; Oshima S; Taniguchi K; Ohe T
Circ J; 2007 Aug; 71(8):1250-7. PubMed ID: 17652890
[TBL] [Abstract][Full Text] [Related]
7. [Bepridil: importance of serum level in treatment surveillance].
Viallon A; Laporte-Simitsidis S; Pouzet V; Venet C; Tardy B; Zéni F; Bertrand JC
Presse Med; 2000 Apr; 29(12):645-7. PubMed ID: 10780196
[TBL] [Abstract][Full Text] [Related]
8. Relationship between serum bepridil concentration and corrected QT interval.
Matsui K; Mukai Y; Sakakura K; Wada K; Nakamura T; Kawabata A; Terakawa N; Hayakawa N; Kusano K; Hosomi K; Yokoyama S; Takada M
Int J Clin Pharmacol Ther; 2021 Jan; 59(1):63-70. PubMed ID: 33026317
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of amiodarone versus bepridil in achieving conversion to sinus rhythm in patients with persistent atrial fibrillation: a randomised trial.
Yamase M; Nakazato Y; Daida H
Heart; 2012 Jul; 98(14):1067-71. PubMed ID: 22689712
[TBL] [Abstract][Full Text] [Related]
10. Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms: a multicenter, randomized, placebo-controlled,double-blind study (J-BAF Study).
Yamashita T; Ogawa S; Sato T; Aizawa Y; Atarashi H; Fujiki A; Inoue H; Ito M; Katoh T; Kobayashi Y; Koretsune Y; Kumagai K; Niwano S; Okazaki O; Okumura K; Saku K; Tanabe T; Origasa H;
Circ J; 2009 Jun; 73(6):1020-7. PubMed ID: 19359813
[TBL] [Abstract][Full Text] [Related]
11. Magnitude of increase in QTc interval after initiation of dofetilide in patients with persistent atrial fibrillation is associated with increased rates of pharmacological cardioversion and long-term freedom from recurrent atrial fibrillation.
Huang HD; Waks JW; Steinhaus DA; Zimetbaum P
Heart Rhythm; 2016 Jul; 13(7):1410-7. PubMed ID: 26921760
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of moxifloxacin and its concentration-QT interval relationship modeling in Chinese healthy volunteers.
Xu FY; Huang JH; He YC; Liang LY; Li LJ; Yang J; Yin F; Xu L; Zheng QS; Wang K
Acta Pharmacol Sin; 2017 Nov; 38(11):1580-1588. PubMed ID: 28713157
[TBL] [Abstract][Full Text] [Related]
13. Importance of morphological changes in T-U waves during bepridil therapy as a predictor of ventricular arrhythmic event.
Kurokawa S; Niwano S; Kiryu M; Murakami M; Ishikawa S; Yumoto Y; Moriguchi M; Niwano H; Kosukegawa T; Izumi T
Circ J; 2010 May; 74(5):876-84. PubMed ID: 20354335
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic properties of a single intravenous dose of ibutilide fumarate: a phase I, randomized, open-label, increasing-dose study in healthy Chinese men.
Li Y; Tian L; Huang Y; Hua L
Clin Ther; 2007 Sep; 29(9):1957-66. PubMed ID: 18035195
[TBL] [Abstract][Full Text] [Related]
15. Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm.
Imai S; Saito F; Takase H; Enomoto M; Aoyama H; Yamaji S; Yokoyama K; Yagi H; Kushiro T; Hirayama A
Circ J; 2008 May; 72(5):709-15. PubMed ID: 18441448
[TBL] [Abstract][Full Text] [Related]
16. Potentially modifiable factors of dofetilide-associated risk of torsades de pointes among hospitalized patients with atrial fibrillation.
Naksuk N; Sugrue AM; Padmanabhan D; Kella D; DeSimone CV; Kapa S; Asirvatham SJ; Lee HC; Ackerman MJ; Noseworthy PA
J Interv Card Electrophysiol; 2019 Mar; 54(2):189-196. PubMed ID: 30353374
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological cardioversion of persistent atrial fibrillation with and without a history of drug-resistant paroxysmal atrial fibrillation.
Fujiki A; Sakamoto T; Iwamoto J; Nishida K; Nagasawa H; Mizumaki K; Inoue H
Circ J; 2006 Sep; 70(9):1138-41. PubMed ID: 16936425
[TBL] [Abstract][Full Text] [Related]
18. Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm.
Fujiki A; Tsuneda T; Sugao M; Mizumaki K; Inoue H
Am J Cardiol; 2003 Aug; 92(4):472-5. PubMed ID: 12914884
[TBL] [Abstract][Full Text] [Related]
19. Repetitive evaluation of fibrillation cycle length predicts the efficacy of bepridil for interruption of long-lasting persistent atrial fibrillation.
Aoyama Y; Niwano S; Niwano H; Satoh A; Kishihara J; Ishikawa S; Murakami M; Fukumoto K; Ueno K; Izumi T
Int Heart J; 2011; 52(6):353-8. PubMed ID: 22188708
[TBL] [Abstract][Full Text] [Related]
20. Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation.
Nakazato Y; Yasuda M; Sasaki A; Iida Y; Kawano Y; Nakazato K; Tokano T; Mineda Y; Sumiyoshi M; Nakata Y; Daida H
Circ J; 2005 Jan; 69(1):44-8. PubMed ID: 15635201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
